You are here
The purpose of this costing study was to undertake a Teaching, Training and Research (TTR) cost and activity data collection at a representative sample of Australian hospitals and produce costed data to inform the development of a TTR classification.
As prescribed in Section 225 of the National Health Reform Act 2011 (the Act), the objectives of the IHPA Work Program are to:
- set out IHPA’s work program for the coming year; and
- invite interested persons (including states and territories) to make submissions to the Pricing Authority about the work program up to 30 days after publication.
An extract of Section 225 of the Act is attached at Appendix 1
IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions.
This data plan sets out IHPA’s third rolling Three Year Data Plan, covering the period 2016-17 to 2018-19.
The non-admitted study was comprehensive across a range of settings (e.g. outpatients, community and satellite clinics). Similarly all service streams were included regardless of funding source. This ensured that all services were accounted for and costed appropriately providing an accurate cost of delivering multiple services across multiple settings (e.g. overhead costs are apportioned across all patients).
The costing study on home delivered dialysis was undertaken in 2014. The purpose of the study was to collate and compare the range of costing studies and economic evaluations that have been carried out on these services over the past decade.
The report identifies two key studies - NSW Dialysis Costing Study, conducted in 2008, and Queensland Health Renal Replacement Therapy Costing Study, conducted in 2008 - which are useful in estimating the current costs of home-based dialysis.
PwC and its sub-contractor The Independent Hospital Pricing Authority (IHPA) engaged PwC and its sub-contractor SyRis Consulting to undertake a review and costing study of Australian radiotherapy services. The study was commissioned to determine the reliability of radiotherapy cost data due to its role in the development of associated price weights in both admitted and non-admitted settings.